SELECT PUBLICATIONS

Panda SK, Facchinetti V, Voynova E, Hanabuchi S, Karnell JL, Hanna RN, Kolbeck R, Sanjuan MA, Ettinger R, Liu YJ. Galectin-9 inhibits TLR7-mediated autoimmunity in murine lupus models.  J Clin Invest. 2018 May 1;128(5):1873-1887. doi: 10.1172/JCI97333. Epub 2018 Apr 3.

Wang S, Wang J, Kumar V, Karnell JL, Naiman B, Gross PS, Rahman S, Zerrouki K, Hanna R, Morehouse C, Holoweckyj N, Liu H, Autoimmunity Molecular Medicine Team, Manna Z, Goldbach-Mansky R, Hasni S, Siegel R, Sanjuan M, Streicher K, Cancro MP, Kolbeck R, Ettinger R. IL-21 drives expansion and plasma cell differentiation of autoreactive CD11chiT-bet+ B Cells in SLE. Nat Commun. 2018 May 1;9(1):1758. doi: 10.1038/s41467-018-03750-7.

Forsthuber TG, Cimbora DM, Ratchford JN, Katz E, Stüve O. B Cell‒based therapies in CNS autoimmunity: differentiating CD19 and CD20 as therapeutic targets. Ther Adv Neurol Disord. 2018 Mar 21;11:1756286418761697. doi: 10.1177/1756286418761697. eCollection 2018

Chen D, Gallagher S, Monson NL, Herbst R, and Wang Y. Inebilizumab, a B Cell‒Depleting Anti-CD19 Antibody for the Treatment of Autoimmune Neurological Diseases: Insights from Preclinical Studies. J. Clin. Med. 2016, 5(12), 107; doi:10.3390/jcm5120107

Schiopu E, Chatterjee S, Hsu V, Flor A, Cimbora D, Patra K, Yao W, Li J, Streicher K, McKeever K, White B, Katz E, Drappa J, Sweeny S, Herbst R. Safety and tolerability of an anti-CD19 monoclonal antibody, MEDI-551, in subjects with systemic sclerosis: a phase I, randomized, placebo-controlled, escalating single-dose study. Arthritis Res Ther. 2016 Jun 7;18(1):131. doi: 10.1186/s13075-016-1021-2

Cree BAC, Bennett JL, Sheehan M,  Cohen J, Hartung H-P, Atkas O, Kim HJ, Paul F, Pittock S, Weinshenker  B, Wingerchuk D,  Fujihara K, Cutter G, Patra K, Flor A, Barron G, Madani S, Ratchford JN, Katz E. A placebo-controlled study in neuromyelitis optica – ethical and design considerations. Multiple Sclerosis Journal 2016, Vol. 22(7) 862–872. DOI: 10.1177/ 1352458515620934

Weinshenker BG, Barron G, Behne JM, Bennett JL, Chin PS, Cree BA, de Seze J, Flor A, Fujihara K, Greenberg B, Higashi S, Holt W, Khan O, Knappertz V, Levy M, Melia AT, Palace J, Smith TJ, Sormani MP, Van Herle K, VanMeter S, Villoslada P, Walton MK, Wasiewski W, Wingerchuk DM, Yeaman MR; Guthy-Jackson Charitable Foundation International Clinical Consortium. Challenges and opportunities in designing clinical trials for neuromyelitis optica. Neurology. Challenges and opportunities in designing clinical trials for neuromyelitis optica. 2015 Apr 28;84(17):1805-15. doi: 10.1212/WNL.0000000000001520. Epub 2015 Apr 3.

More publications information will be available soon